Results 131 to 140 of about 127,568 (322)

Initial investigations into single nucleotide polymorphisms and their association with QTc and left ventricular function in peripartum cardiomyopathy

European Journal of Heart Failure, EarlyView.
Gasnat Shaboodien, Charle Viljoen, Polycarp Ndibangwi, Julian Hoevelmann, Lameez Pearce, Susanna Haidari, Margherita Torchio, Federica Dagradi, Carla Spazzolini, Sarah Kraus, Ntobeko A.B. Ntusi, Peter J. Schwartz, Karen Sliwa   +12 more
wiley   +1 more source

Blubber Thickening Driven by UCP1 Inactivation: Insights from a Cetacean‐Like Transgenic Mouse Model

Integrative Zoology, EarlyView.
UCP1 inactivation of cetaceans in mice drives BAT whitening and iWAT hyperplasia, promoting fat accumulation for aquatic adaptation. Abstract Cetaceans possess thick blubber, a specialized adipose tissue essential for thermal insulation, a streamlined body form, energy storage, and buoyancy. However, the mechanisms that underpin this adaptation are not
Qian Zhang, Yuehua Wang, Hang Zhang, Guiping Xu, Shixia Xu, Guang Yang   +5 more
wiley   +1 more source

Non‐canonical PKG1 regulation in cardiovascular health and disease

British Journal of Pharmacology, EarlyView.
It is well established that the cyclic GMP‐dependent protein kinase I (PKG1) is canonically activated by cyclic guanosine monophosphate (cGMP), enabling its regulation of vascular tone, cardiac function and smooth muscle homeostasis. However, diverse non‐canonical stimuli of PKG1 have also been identified.
Jie Su, Joseph Robert Burgoyne
wiley   +1 more source

Allele-specific dysregulation of lipid and energy metabolism in early-stage hypertrophic cardiomyopathy

Journal of Molecular and Cellular Cardiology Plus
Introduction: Hypertrophic cardiomyopathy (HCM) results from pathogenic variants in sarcomeric protein genes that increase myocyte energy demand and lead to cardiac hypertrophy.
Arpana Vaniya, Anja Karlstaedt, Damla Gulkok, Tilo Thottakara, Yamin Liu, Sili Fan, Hannah Eades, Styliani Vakrou, Ryuya Fukunaga, Hilary J. Vernon, Oliver Fiehn, M. Roselle Abraham   +11 more
doaj   +1 more source

Diagnosis of some diseases through biomarkers [PDF]

, 2019
Muchos gatos, como los perros, sufren de diferentes enfermedades. que en ese momento no permiten mostrar síntomas o signos que permiten identificar que la mascota sufre una enfermedad grave, ya que las características de los gatos son diferentes a las de
Gutiérrez Rodríguez, Andrea
core  

Leveraging the ADAM10 prodomain for selective inhibition to enhance recovery after myocardial infarction

British Journal of Pharmacology, EarlyView.
Background and Purpose Inflammation plays a crucial role in the development and progression of numerous acute and chronic diseases such as myocardial infarction (MI) and heart failure. Targeting ADAM proteases, particularly ADAM10, holds promise for fine‐tuning inflammatory responses.
Erik Klapproth, Johanna Marks, Patrick Diaba‐Nuhoho, Sören Grell, Paul Leubauer, Susanne Kämmerer, Johannes R. Soltwedel, Fred Rasmussen, Felix Mejia, Marcia L. Moss, Christopher Prince, Peter Mirtschink, Ben Wielockx, Paul Saftig, Michael Wagner, Kristina Lorenz, Ali El‐Armouche   +16 more
wiley   +1 more source

Deep learning‐enhanced 3D imaging unveils semaglutide impact on cardiac fibrosis

British Journal of Pharmacology, EarlyView.
Background and Purpose Myocardial fibrosis (MF), a hallmark of structural cardiac remodelling, drives disease progression across most forms of heart failure and plays a central role in heart failure with preserved ejection fraction (HFpEF). Despite its clinical relevance, effective treatments remain scarce.
Sheyla Barrado‐Ballestero, Sarah Torp Yttergren, Max Hahn, Marie Biviano Rosenkilde, Ditte Marie Jensen, Michael Christensen, Louise Thisted, Heidi Lindgreen Holmberg, Geoffrey Teixeira, Tor Biering‐Sørensen, Casper Gravesen Salinas, Urmas Roostalu   +11 more
wiley   +1 more source

Transcriptional and functional effects of mavacamten in multiple porcine and human models with hypertrophic cardiomyopathy

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Mavacamten (MAVA) is a novel small molecule inhibitor of cardiac myosin, mitigating cardiomyocyte hypercontractility in patients with hypertrophic obstructive cardiomyopathy (HOCM). Despite its recent approval for clinical use, the transcriptional and functional impacts of MAVA remain not well understood.
Elisa Kiselev, Wilson Agyapong, Bjarne Jürgens, Elisa Mohr, Shambhabi Chatterjee, Hannah J. Hunkler, Jawad Salman, Giuseppe Cipriano, Marco Bentele, Junqing Liu, Jonas Specht, Kaja S. Menge, Florian J. G. Waleczek, Jonas A. Haas, Anselm A. Derda, Kristina Sonnenschein, Anika Gietz, Susanne Neumüller, Angelika Pfanne, Oliver Beetz, Michael Pflaum, Bettina Wiegmann, Yiangos Psaras, Christopher Toepfer, Robert Zweigerdt, Ante Radocaj, Theresia Kraft, Andre Zeug, Evgeni Ponimaskin, Wilhelm Korte, Alexander Horke, Arjang Ruhparwar, Maximilian Fuchs, Ke Xiao, Christian Bär, Natalie Weber, Thomas Thum   +36 more
wiley   +1 more source

Evaluation of red blood cell distribution width in cats with hypertrophic cardiomyopathy [PDF]

, 2015
Connolly, D J, Cowlam, R, English, K, Stanzani, G   +3 more
core   +1 more source

Impact of Coronary Artery Anatomy on Clinical Course and Prognosis in Apical Hypertrophic Cardiomyopathy: Analysis of Coronary Angiography and Computed Tomography [PDF]

, 2015
Dong Geum Shin, Jung‐Woo Son, Ji Young Park, Jae Woong Choi, Sung Kee Ryu   +4 more
openalex   +1 more source